Secondary haemochromatosis in a haemodialysis patient.
- Author:
Lu CHENG
1
;
Xi TANG
1
;
Ping FU
1
;
Fang LIU
1
Author Information
- Publication Type:Case Reports
- Keywords: ESRD; HFE gene; deferoxamine; haemodialysis; secondary haemochromatosis
- MeSH: Adult; Chelating Agents; chemistry; Erythropoietin; therapeutic use; Female; Ferritins; blood; Hemochromatosis; complications; Hemoglobins; analysis; Humans; Kidney Failure, Chronic; complications; therapy; Recombinant Proteins; therapeutic use; Renal Dialysis; adverse effects; Sequence Analysis, DNA; Tomography, X-Ray Computed; Transferrin; chemistry; Transfusion Reaction; Treatment Outcome
- From:Singapore medical journal 2015;56(7):e124-6
- CountrySingapore
- Language:English
- Abstract: A 39-year-old woman with end-stage renal disease, which was maintained on haemodialysis, developed secondary haemochromatosis after receiving blood transfusions and intravenous iron supplementation without sufficient serum ferritin concentration monitoring. The patient received intravenous deferoxamine three times a week, combined with high-dose recombinant human erythropoietin therapy and haemodialysis. After three months, improvements in biochemical indicators and iron overload were noted.
